Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neoadjuvant, Adjuvant and 1st Line”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Ended earlyNCT00461344
What this trial is testing

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Who this might be right for
Ductal Carcinoma
Sanofi 20
Testing effectiveness (Phase 2)Ended earlyNCT00620100
What this trial is testing

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Who this might be right for
Breast Neoplasms
Sanofi 2
Not applicableStudy completedNCT04896931
What this trial is testing

New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

Who this might be right for
Biliary Tract CancerNeoadjuvant, Adjuvant and 1st Line
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 159
Testing effectiveness (Phase 2)Study completedNCT04570410
What this trial is testing

Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

Who this might be right for
Bladder Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University 30

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation